Background: Raised resting heart rate (HR), >70 beats per minute (bpm), has been shown to be a risk factor for adverse cardiovascular outcomes and hospital readmissions, specifically in patients with heart failure with reduced ejection fraction (HFrEF). Given their mortality benefit, b-blockers are recommended in HFrEF, with a goal to titrate to a maximum tolerated dose rather than a specific HR target. Objective: To determine the impact of optimal HR control achievement prior to hospital discharge on hospital readmissions in patients with HFrEF receiving b-blockade. Methods: A retrospective study of patients admitted to 5 adult hospitals within a large urban health-care system, between 2013 and 2015, was conducted. Patients were identified via International Classification of Diseases, Ninth Revision (ICD-9) coding for acute on chronic HFrEF. Results: Of the 225 patients included, 20% achieved optimal HR control (n ¼ 46, HR <70 bpm; n ¼ 179, HR 70 bpm) and only 15% received b-blocker titration during hospital admission. Of note, 25% of patients receiving 50% target dose (n ¼ 79) and 28% receiving 100% target dose (n ¼ 39) achieved optimal HR control. At 30 days, patients with an HR <70 bpm versus HR 70 bpm exhibited similar readmission rates (9% vs 11%, respectively; P > .99) and ED visits (11% vs 8%, respectively; P ¼ .57). Conclusions: Readmission rates were similar among patients with HFrEF despite the majority failing to achieve optimal HR control from b-blockade. However, b-blocker dosing remains suboptimal relative to guideline-recommended target doses. Opportunities exist for inpatient clinicians to optimize b-blockade in an attempt to achieve HR control.
Introduction
Heart failure (HF) has been described as a major public health issue, with over 2.4 million hospitalized patients having HF as a primary or secondary diagnosis and serving as the most common hospital diagnosis in the elderly. 1 In an effort to decrease this disease burden, the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines recommend standard treatment regimens consisting of diuretics, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and b-blockers for all patients with HF with reduced ejection fraction (HFrEF). 2 Despite advances in evidence-based therapeutic management, patients admitted with acute decompensated HF remain at high risk of hospital readmission, with approximately 25% readmitted within 30 days. 3 Since their landmark clinical trials showing a reduction in all-cause mortality, certain b-blockers (bisoprolol, metoprolol succinate, and carvedilol) have been a standard of care for patients with HFrEF, with a goal of titrating to maximum tolerated doses established in the studies. [4] [5] [6] [7] Not only is this strategy problematic due to increased adverse effects secondary to higher dosages but also previous studies have indicated that only a small number of patients achieve these high doses in clinical practice outside specialized HF clinics. 8, 9 Newer evidence has started to accumulate indicating that heart rate (HR) reduction, rather than the b-blocker dose achieved, is a better predictor of prognosis given the negative cardiovascular consequences of long-standing elevated HR. [10] [11] [12] A large meta-analysis in patients with HFrEF receiving b-blockers found an 18% reduction in mortality for every 5 beats per minute (bpm) reduction in HR and no correlation between all-cause mortality and target b-blocker dose achieved. 13 Subsequent studies have also indicated that achievement of target b-blocker dose is unrelated to achievement of target HR. 14, 15 Given this lack of correlation, the question may be raised whether it would be more prudent to titrate to a recommended HR rather than a maximum tolerated b-blocker dose, as is currently the standard of practice.
With the recent US Food and Drug Administration approval of ivabradine, a novel agent which blocks the I f currents in the sinus node resulting in HR reduction without appreciable effects on blood pressure, a larger focus has been placed upon HR control in the HFrEF population. 16 Updated ACC/AHA/ Heart Failure Society of America guidelines recommend ivabradine to reduce HF hospitalizations in patients with HFrEF with a HR 70 bpm despite receiving a maximally tolerated dose of a b-blocker. 17 As is often seen in clinical practice, maximum tolerated b-blocker doses may be significantly lower than the mean doses achieved in clinical trials. This was also observed in the Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT), with only 26% of patients receiving target b-blocker dosages and 56% receiving 50% target dosages. 18 Given their mortality benefit, b-blockade should be maximized before adding an additional agent for HR control, such as ivabradine, that may increase polypharmacy and adversely affect medication compliance. The new HF guideline recommendations coupled with ivabradine evidence, both focusing on a reduction in HF readmissions, have helped shed light on the importance of focusing on HR control in the HFrEF population. The main objective of this study was to determine the impact of optimal HR achievement, secondary to b-blocker use, on hospital readmissions in patients with HFrEF.
Materials and Methods

Patient Selection and Study Design
A retrospective review of patients admitted to 1 of 5 adult hospitals within a large urban health-care system between September 1, 2013, and September 1, 2015 was conducted. Patients with a primary diagnosis of acute on chronic HFrEF were identified utilizing International Classification of Diseases, Ninth Revision (ICD-9) codes. The diagnosis was further confirmed by chart review for physician documentation of acute on chronic HFrEF, and patients were subsequently evaluated for inclusion. The study was approved by the University of Tennessee Health Science Center institutional review board and received no financial grants or support from outside sources.
Patients 18 years of age or older, admitted for acute on chronic HFrEF, and receiving at least 48 hours duration of the same b-blocker during hospitalization were included. Only patients receiving ACCF/AHA HF guideline recommended b-blockers (metoprolol succinate, bisoprolol, carvedilol) were reviewed. Patients were also required to be discharged on an appropriate HFrEF regimen, which consisted of a loop diuretic, ACE inhibitor or ARB, and b-blocker. Included patients' data were recorded during their initial hospitalization and then monitored for readmissions. If patients were readmitted during the study period, they were not counted more than once and were subsequently excluded from the study population. Further exclusion criteria consisted of patients with decompensated HF (intensive care unit [ICU] admission or dobutamine administration during index hospitalization), an implantable pacemaker or history of atrial fibrillation, and those experiencing hypotension or bradycardia upon admission or mortality within the index hospitalization. In addition, patients receiving additional rate controlling agents (eg, verapamil or diltiazem) and patients with known noncompliance (as documented in the History and Physical or the medication history in the electronic medical record) were excluded.
All included patients were assigned to 1 of 2 groups based upon discharge HR, which was defined as the last HR captured in the medical record before discharge. Optimal HR control was defined as a discharge HR <70 bpm. Therefore, patients who achieved a discharge HR <70 bpm were assigned to the optimal HR control group and those who exhibited a discharge HR 70 bpm were assigned to the suboptimal HR control group.
Data Collection and Definitions
Patient demographics including race, age, sex, and weight were recorded, along with assessment of vital sign data, such as admission and discharge HR and blood pressure. Admission and discharge b-blocker dose, along with duration of therapy, was also evaluated. Utilizing these data, the percentage of target b-blocker dose the patients were receiving upon discharge was calculated. Other data collected from the medical record included pertinent medical history, use of other HF medications upon admission and discharge, HF readmissions, and emergency department (ED) visits.
Target b-blocker dosages were defined as bisoprolol 10 mg daily, carvedilol 25 mg twice daily, carvedilol-controlled release 80 mg once daily, and metoprolol succinate 200 mg once daily. Hypotension was defined as a systolic blood pressure <90 mm Hg, and bradycardia was defined as a HR <60 bpm. The 30-day and 90-day readmission data were determined by subsequent readmissions within the hospital system and only assessed if the primary indication for readmission was due to HF.
Outcomes
The primary outcome of this study was to compare the 30-day readmission rates for patients taking b-blockers who achieved optimal HR control to those with suboptimal HR control. Secondary outcomes included 90-day readmission rates and ED visits for patients who achieved optimal HR control compared to those with suboptimal HR control, readmission rates in patients receiving less than 50% and greater than 50% target b-blocker dose, and rate of hypotension and bradycardia during index hospitalization.
Continuous parametric data sets are presented as mean + standard deviation and were analyzed using a Student t test. Nominal data were analyzed either using the w 2 test or Fisher exact test. Incidence of 30-day and 90-day readmission, as well as hypotension and bradycardia occurrence, was compared between the optimal HR control group and the suboptimal HR control group utilizing a w 2 test. Two-tailed statistical tests were utilized and a P <.05 was determined to represent statistical significance. Data were analyzed using SPSS Statistics for Windows, version 21 (IBM Corporation, Armonk, New York).
Results
Overall, 3378 admissions were screened with 225 patients meeting inclusion criteria. Of the 225 HFrEF admissions, 46 patients had optimal HR control at discharge and 179 patients had suboptimal HR control (Figure 1) . Baseline demographics are shown in Table 1 . The majority of the patient population was African American (82%) with preexisting HFrEF (73%). Patients who achieved optimal HR control were significantly older than those with suboptimal control. Admission diastolic blood pressure and admission HR were significantly higher in patients who were discharged with suboptimal HR control. Average length of stay was 5.0 + 3.0 days with an average b-blocker treatment duration of 4.1 + 2.7 days.
The most common b-blocker received was carvedilol (95%) with an average discharge dose of 10 + 8.3 mg twice daily, followed by metoprolol succinate (5%) with an average discharge dose of 33 + 14.0 mg once daily. No patients received bisoprolol or carvedilol controlled release. b-Blocker characteristics are summarized in Table 2 . Overall, the majority of patients received <50% target b-blocker dose (65%), with only 17% receiving 100% target dose. Target b-blocker dosages achieved relative to attainment of optimal HR are shown in Figure 2 . There was no significant difference noted in achievement of optimal HR control and target b-blocker dose achieved (25% 50% target dose group vs 18% < 50% target dose group; P ¼ .23).
In assessing 30-day HF readmission rates, there was no significant difference between the optimal HR control group and the suboptimal HR control group (9% vs 11%, respectively; P > .99). Similarly, there was no significant difference in 90-day HF readmissions (28% optimal HR control group vs 26% suboptimal HR control group; P ¼ .71). Patients with a 30-day or 90-day readmission are shown in Figure 3 . Secondary analysis of HF ED visits after index hospitalization also revealed no significant difference in 30 days (11% optimal HR Abbreviation: BP, blood pressure; bpm, beats per minute; HF, heart failure; HR, heart rate.
control group vs 8% suboptimal HR control group; P ¼ .57) or 90 days (20% optimal HR control group vs 26% suboptimal HR control group; P ¼ .45). Examining outcomes based upon b-blocker dose achieved, patients receiving 50% target dose exhibited similar 30-day readmission rates compared to those receiving <50% target dose (9% vs 11%, respectively; P ¼ .82). Ninety-day readmission rates were similar as well (25% 50% target dose group vs 27% < 50% target dose group; P ¼ .87). Readmission rates by target b-blocker dose achievement are shown in Figure 3 .
In terms of adverse effects, patients with optimal HR control at discharge experienced significantly more bradycardia during index hospitalization than those with suboptimal control (52% vs 15%, respectively; P < .0001). While incidence of hypotension was also increased in the optimal HR control group, this was not a significant finding (63% vs 47%; P ¼ .07).
Discussion
Our study showed that regardless of discharge HR, patients achieving optimal HR control did not experience a decrease in hospital readmissions. Although meta-analyses have revealed an association between all-cause mortality and HR, there is a paucity of data assessing the correlation of HR reduction secondary to b-blocker use and HF readmissions. 12, 13 Laskey and colleagues examined records of more than 26 000 Medicare patients with HFrEF discharged in normal sinus rhythm and found an independent association between discharge HR 75 bpm and a composite of all-cause readmission and mortality at both 30 and 365 days after discharge. 19 However, this composite was mainly driven by a reduction in mortality. Unlike our study, Laskey and colleagues assessed all-cause readmissions rather than HF readmissions. This correlation was further described in the SHIFT trial observing ivabradine use in 6558 patients with HFrEF with a lower average admission HR compared to our study (HR ¼ 80 bpm SHIFT vs HR ¼ 92 bpm in our study). 18 The primary composite end point of cardiovascular death or HF hospital admission was significantly reduced with ivabradine compared to placebo (hazard ratio: 0.82, 95% confidence interval: 0.75-0.90). The primary end point was driven mainly by a significant reduction in HF hospital admissions (16% ivabradine vs 21% placebo), as all-cause mortality was not significant. Subgroup analysis revealed a significant treatment effect only for patients with a baseline HR higher than the median 77 bpm and a 16% increase in the risk of primary composite end point for every 5 bpm increase from baseline HR. 20 Although this trial did show positive results for HR control reducing HF readmissions, it is important to note that this was mainly attributed to a combination effect, as 90% of patients were also receiving b-blocker therapy, albeit only 26% were receiving target doses. Our findings when analyzing the effect of HR control secondary to bblockade alone do not align with the results of the SHIFT trial which may be the result of a small number of our patients achieving optimal HR control prior to discharge.
Given previous findings of the negative consequences associated with elevated HR, it is concerning only 20% of our population achieved optimal HR control prior to discharge. DeVore and colleagues also described this phenomenon in 10 696 patients with HF receiving b-blockers from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registry and found that 71% of patients had an elevated HR at discharge, 63% of which were discharged on at least 50% target dose of b-blocker. 21 The authors ultimately concluded that the period surrounding hospital discharge is a unique time to identify and intervene on patients with HFrEF with elevated HR. Lack of intervention played a major role in patients failing to achieve optimal HR control in our study with only 15% receiving a dose titration during their inpatient stay. Our study helps highlight the opportunities available to clinicians for prompt recognition and intervention of suboptimal HR control in the inpatient setting to help limit future negative HF outcomes.
Heart rate control literature or guideline unawareness, concern for b-blocker adverse effects, or deferment to outpatient management could all play a role in inpatient clinicians failing to titrate b-blockers. Dose-limiting adverse effects could also play a role in preventing patients from achieving optimal HR control via b-blockers alone. As seen in our study, bradycardia Abbreviation: HR, heart rate.
was significantly increased in patients who achieved optimal HR control, and although not statistically significant, rates of hypotension were increased as well. Moran and colleagues also helped elucidate reasons for failure to achieve target b-blocker doses in an analysis of 549 patients from 12 HF clinics. 14 The majority of patients cited dyspnea (34%) or hypotension (22%) as the main dose-limiting adverse effect. Surprisingly, bradycardia was only cited in 8% of patients, compared to 22% seen in our population as a whole. We did define bradycardia as a HR < 60 bpm at any point during the hospitalization and may have overestimated the true prevalence of sustained bradycardia in doing so. Asymptomatic HR < 60 bpm may be deemed acceptable in clinical practice, and there is some evidence for targeting a lower HR (<60 bpm) to improve outcomes. 20 Rather than straying from titrating due to negative stigmata associated with b-blockers, inpatient clinicians should instead be vigilant in titrating b-blockers while assessing patients for adverse effects to ensure that patients are not symptomatic secondary to bradycardia or hypotension. One concern for inpatient practitioners may be aggressive titration in the setting of sustained acute HF exacerbation, as some patients may require a higher HR to support cardiac output. To avoid limiting this compensatory response, titrations may be best reserved for once the acute HF exacerbation begins to resolve and the patient nears their baseline functional status. Our study attempted to eliminate those with more severe exacerbations who may require a higher HR by excluding those with an ICU admission or requiring dobutamine administration.
There are several limitations to this study that should be considered when interpreting the results. First, this was a retrospective study which relied on ICD-9 code for diagnosis of acute on chronic HFrEF. However, we did further confirm the diagnosis based on physician documentation of acute on chronic HFrEF. While over 3000 patients were screened, only 225 met inclusion criteria, with only a small percentage achieving optimal HR control prior to discharge which may have caused our study to be underpowered to determine a true difference in readmission rates between the 2 groups. Furthermore, a vast majority of our patients were receiving carvedilol; therefore, these results may not be generalizable to the use of other b-blockers approved for HF. It is important to note that a large majority of our population was greater than 85 kg (n ¼ 139), which may indicate a maximum dose of carvedilol 50 mg twice daily per package labeling. 22 However, we chose carvedilol 25 mg twice daily as our target dose in all patients, regardless of weight, as it is the maximum dose most validated in the HFrEF literature. 4, 7, 23, 24 We were also unable to assess a true resting HR, as many confounding variables exist within the inpatient setting, such as stress or infection. Despite being unable to control for these variables, we were consistent in determining discharge HR and felt that the last set of vitals captured in the medical record frequently serve as the basis for determining pharmacotherapy regimens upon discharge. Furthermore, readmission data could only be abstracted based upon hospital readmissions within our health system which could potentially underestimate the true readmission data. Finally, we were unable to assess for outpatient noncompliance which can negatively impact hospital readmissions.
Despite these limitations and lack of positive readmission findings, this study has the potential to raise awareness on the lack of achievement of optimal HR control in hospitalized HFrEF patients, which should be a priority given previously identified negative cardiovascular outcomes associated with elevated HR. This study also has the potential to influence inpatient clinicians to intervene on suboptimal HR control more promptly via b-blocker titration. Regardless of the titration strategy chosen, inpatient clinicians should closely examine their own practices to ensure that b-blockade is optimized in patients with HFrEF prior to discharge.
Conclusion
Readmission rates were similar among patients with HFrEF irrespective of achievement of optimal HR control. However, our study highlights the need for more prompt recognition and intervention of suboptimal HR control in patients with HFrEF in the inpatient setting, as both HR control and b-blocker dosing were relatively subpar compared to guideline recommendations. Given that previous literature has shown a correlation between elevated HR and negative cardiovascular outcomes, clinicians should strive to optimize b-blockers in patients with HFrEF prior to hospital discharge. Due to the small number of patients achieving optimal HR control prior to hospital discharge, it is likely that our study was underpowered to detect a true readmission rate difference. Therefore, larger, randomized studies are needed to determine the true relevance of targeting a goal HR versus target b-blocker dose in clinical practice and its impact on hospital readmissions. As seen with our study, these 2 strategies do not necessarily correlate and may be mutually exclusive entities, which demonstrates a need for more evidence to discern the optimal strategy for managing b-blockade in patients with HFrEF.
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